Zomedica Q2 2022 revenue $4.2M, up 51% pro-forma; net loss $5.3M, cash $186.8M

Zomedica Corp.

2022-Q2 EPS reported -$0.01 revenue$7,997,000

Revenue $4.2M (71% gross margin), up 51% pro-forma vs combined $2.8M in Q2 2021.
PulseVet revenue $4.2M (+48% standalone); small animal systems sold 22 (20x increase).
Net loss $5.3M ($0.005/sh) vs $4.7M loss in Q2 2021; 6-month loss $9.2M ($0.009/sh).
Cash $186.8M; used $5.5M in quarter including $1M convertible note in SMP (VetGuardian).
Post-quarter acquisitions: Revo 2 imaging assets and Assisi LOOP/Calmer Canine products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.